Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | NK-92/5.28.z |
| Trade Name | |
| Synonyms | HER2.taNK|Anti-HER2-CAR-CD28zeta NK-92 Cells |
| Drug Descriptions |
NK-92/5.28.z are NK-92 natural killer cell line-derived cells engineered to express a chimeric antigen receptor (CAR) that targets ERBB2 (HER2) and contains CD28 and the signaling domain from CD3zeta, which potentially results in tumor cell cytotoxicity and inhibition of tumor growth (PMID: 28879551, PMID: 25373520). |
| DrugClasses | HER2 (ERBB2) Immune Cell Therapy 9 |
| CAS Registry Number | NA |
| NCIT ID | C154568 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Ezabenlimab + NK-92/5.28.z | Ezabenlimab NK-92/5.28.z | 0 | 1 |
| NK-92/5.28.z | NK-92/5.28.z | 0 | 0 |